Extraordinary advances are happening at the Mount Sinai Health System, and we want you to be among the first to know. Mount Sinai Physician’s Channel will show you some of the innovative procedures, developments in patient care, and complex cases that are being handled in our world-class facilities. We invite you to come back often to stay on top of what’s new in your specific field.
Featured Items
New Content
Uncovering the Roots of Alzheimer’s Disease
Department of Genetics and Genomic Sciences at Mount Sinai researchers are uncovering how microglia—immune cells in the brain—contribute to Alzheimer’s disease. Led by Alison Goate, DPhil, the team identified genes and regulators tied ...
Precision in Practice: Shaping the Future of Individualized Care
Mount Sinai researchers are advancing precision medicine by developing patient-specific tumor models, AI-driven drug repurposing pipelines, and interactive tools to improve diagnostics, treatment prediction, and therapeutic discovery across diverse diseases.
Advancing Precision Therapies for Rare Metabolic Disorders
Eva Morava, MD, PhD, and Tamas Kozicz, MD, PhD, are advancing therapies for rare metabolic disorders using organoid models and clinical trials—bringing personalized treatments to patients with congenital disorders of glycosylation and mitochondrial diseases.
From Genome to Diagnosis: Finding Answers for the Undiagnosed
The Turro Lab is uncovering the genetic roots of rare and undiagnosed diseases using advanced genome sequencing and statistical methods—offering long-sought answers to families and driving the discovery of new genetic syndromes that impact ...
Connecting Genomes and Microbes to Unlock New Therapies
The Center for AI-Driven Genomic and Microbiome Medicine unites genomic and microbiome research to advance precision medicine—using tools like long-read sequencing and strain-level analysis to uncover how these systems interact and influence ...
Getting Ahead of Crohn’s Disease
The PROMISE Consortium is redefining Crohn’s disease care by identifying early biomarkers through multi-omic, microbiome, and immune system research—shifting the focus from treatment to prediction and prevention.
Powering Precision Medicine with AI - For Everyone
Dr. Kuan-lin Huang’s lab is using AI and machine learning to improve disease risk prediction and treatment - integrating rare and common genetic variants from diverse populations to power more accurate, equitable, and individualized approaches ...
Redefining What’s Possible in Rare Disease Clinical Trials
Mount Sinai’s Genetics and Genomics faculty are leading transformative clinical trials—advancing gene therapies, disease-modifying treatments, and precision interventions for rare diseases, childhood disorders, and chronic conditions—bringing ...
Frontiers in Discovery and Care: Genetics and Genomic Sciences 2025
Cutting-edge research, and clinical innovations from Mount Sinai’s Department of Genetics and Genomic Sciences
Date: Wednesday, June 25, 2025 | Time: 1:00 – 2:00 pm
AI-Driven Model Supports Safer and More Precise Blood Sugar Management After Heart Surgery
New research shows machine learning can assist doctors in navigating complex insulin dosing in the ICU
Study provides robust evidence of increased risk in full siblings, suggesting both genetic and shared environmental influences
The Friedman Brain Institute Spring 2025
It has long been known that the brain communicates with all other organs in the body. Historically, this work focused on the brain’s control of the pituitary gland and the many peripheral hormones it governs, and of the autonomic nervous ...
Work establishes new paradigm for studying drug addiction with naturalistic stimuli that resemble the real, lived experiences of patients
Mount Sinai-led study leads to improved understanding of risk
Mount Sinai researchers have discovered distinct roles for two dopamine receptors located on nerve cells within the portion of the brain that controls approach vs. avoidance behavior. These receptors potentially influence anxiety and mood ...
Mount Sinai study suggests COVID-19 infection should be considered a risk factor for future cardiopulmonary conditions